---
title: "UM171‑Expanded Cord Blood Transplantation for High‑Risk Acute Leukemia and MDS in Adults"
id: "medrxiv-18-um171-expanded-cord-blood-transplantation-in-adults-with-high-and-very-high"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-um171-expanded-cord-blood-transplantation-in-adults-with-high-and-very-high"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.21.26360802v1?rss=1"
published_at: "2026-08-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# UM171‑Expanded Cord Blood Transplantation for High‑Risk Acute Leukemia and MDS in Adults
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-um171-expanded-cord-blood-transplantation-in-adults-with-high-and-very-high
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.21.26360802v1?rss=1)
- **Published At:** 2026-08-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Two prospective, single‑arm phase II trials evaluated single‑unit **UM171‑expanded cord blood (CB)** transplantation in adults with high‑ or very high‑risk acute leukemia (AL) or myelodysplastic syndrome (MDS). - Sixty of 64 enrolled patients received a manufactured UM171‑expanded CB graft and comprised the analysis population; cord units were preferentially selected at a 5/8 HLA match to maximize graft‑versus‑leukemia effect. - Patients received intermediate‑ or high‑intensity conditioning and tacrolimus/mycophenolate mofetil for graft‑versus‑host‑disease (**GVHD**) prophylaxis. - Median time to neutrophil engraftment was 17 days and to platelet engraftment was 38 days, indicating prompt hematopoietic recovery after expansion and infusion. - Non‑relapse mortality (**NRM**) was 5.1% at day 100 and 15.2% at 1 year. - Two‑year cumulative incidence of relapse was 22.3%; two‑year overall survival (**OS**) was 63.9% and relapse‑free survival (**RFS**) was 60.4%. - Incidence of grade III–IV acute **GVHD** was 20.3% at 1 year; moderate‑to‑severe chronic GVHD incidence was 6.8% at 2 years, indicating relatively infrequent clinically significant chronic GVHD. - The study population included patients with prior transplantation (32%), active disease at transplant (17% of AL patients), and adverse biology such as TP53 mutations (24% among AML/MDS), reflecting a high‑risk cohort. - The trials demonstrated feasibility of manufacturing and infusion for nearly all eligible patients and support further comparative studies to define the role of UM171‑expanded CB relative to contemporary donor platforms. - All relevant ethical approvals were obtained; trials are registered (NCT03913026, NCT04103879). Data are available on reasonable request. Competing interests and industry affiliations related to ExCellThera and UM171 are disclosed in the source.
## Clinical Analysis & Structured Key Points
UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials | medRxiv Skip to main content UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials Sandra Cohen , Elisa Tomellini , Nadia Bambace , Imran Ahmad , Lea Bernard , Jean Roy , Jonathan Gutman , Jurjen Versluis , Pierre Caudrelier , Gabrielle Thauvette , Guy Sauvageau , Filippo Milano doi: https://doi.org/10.64898/2026.08.21.26360802 Sandra Cohen 1 Division of Haematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: sandra.cohen.med{at}ssss.gouv.qc.ca Elisa Tomellini 2 ExCellThera, Montreal, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nadia Bambace 3 Institut universitaire d'hemato-oncologie et de therapie cellulaire, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Imran Ahmad 3 Institut universitaire d'hemato-oncologie et de therapie cellulaire, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lea Bernard 3 Institut universitaire d'hemato-oncologie et de therapie cellulaire, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jean Roy 3 Institut universitaire d'hemato-oncologie et de therapie cellulaire, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jonathan Gutman 4 University of Colorado School of Medicine. Anschutz Medical Campus. Aurora. CO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jurjen Versluis 5 Erasmus University Medical Center Cancer Institute, University of Rotterdam, Rotterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pierre Caudrelier 2 ExCellThera, Montreal, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gabrielle Thauvette 2 ExCellThera, Montreal, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Guy Sauvageau 6 Institut de recherche en immunologie et cancerologie, University of Montreal, Montreal, QC, Canada; Institut universitaire d'hemato-oncologie et de therapie cellulaire, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Filippo Milano 7 Fred Hutchinson Cancer Center. University of Washington School of Medicine, Seattle, WA, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Purpose: Adults with high- or very high-risk acute leukemia (AL) or myelodysplastic syndrome (MDS) face substantial relapse risk after allogeneic hematopoietic stem-cell transplantation. We evaluated single-unit cord blood (CB) transplantation after ex vivo expansion with UM171 in this population. Patients and Methods: Two prospective, single-arm phase II trials at four centers enrolled 64 adults with high- or very high-risk AL or MDS; 60 received a UM171-expanded CB transplant and comprised the analysis population. CB units were preferentially selected at a 5/8 HLA match to maximize the graft versus leukemia effect. Patients received intermediate- or high-intensity conditioning with tacrolimus/mycophenolate mofetil graft-versus-host-disease (GVHD) prophylaxis. Endpoints included safety, feasibility, non-relapse mortality (NRM), relapse-free survival (RFS), overall survival (OS), GVHD, GVHD-free relapse-free survival (GRFS), chronic GVHD-free relapse free survival (CRFS). Results: Thirty-two percent of patients had undergone previous transplantation, 17% of patients with AL were not in remission and 24% of those with AML/MDS had TP53 mutations. Of 62 patients who remained eligible for transplantation, 60 had a graft successfully manufactured and infused. Median times to neutrophil and platelet engraftment were 17 and 38 days, respectively. NRM was 5.1% at day 100 and 15.2% at 1 year. Two-year cumulative incidence of relapse was 22.3%. Two-year OS and RFS were 63.9% and 60.4%, respectively. Grade III-IV acute GVHD incidence was 20.3% at 1 year and moderate-to-severe chronic GVHD incidence was 6.8% at 2 years. Conclusion: UM171-expanded CB transplantation was feasible and provided prompt engraftment, durable disease control, and infrequent clinically significant chronic GVHD in adults with high- and very high-risk AL/MDS. Comparative studies are warranted to define its role relative to contemporary donor platforms. Competing Interest Statement S.C. has received consulting fees and clinical trial funding from ExCellThera and is entitled to receive royalties from sales of UM171. J.R. has received clinical trial funding from ExCellThera, is entitled to receive royalties from sales of UM171, and has served as a consultant for Amgen, Sanofi, Janssen, and Forus Therapeutics. G.S. is a stockholder and Chief Scientific Officer of ExCellThera and is entitled to receive royalties from sales of UM171. F.M. has received clinical trial funding from ExCellThera. E.T. is Director of the Research and Development Laboratory at ExCellThera; P.C. is Chief Medical Officer of ExCellThera; and G.T. is Manager of Quality and Data at ExCellThera. I.A. has served as a consultant for AbbVie, Jazz Pharmaceuticals, Medexus, Sanofi, and Vertex Pharmaceuticals. N.B. has served as a consultant for AbbVie and Omeros. ExCellThera holds the license for UM171. All remaining authors declare no competing interests. Clinical Trial NCT03913026 NCT04103879 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Research Ethics Board of Hopital Maisonneuve-Rosemont gave ethical approval for the ECT-002 study. The Institutional Review Board of Fred Hutchinson Cancer Center gave ethical approval for the ECT-004 study. WCG IRB gave ethical approval for the work conducted at the University of Colorado School of Medicine, Anschutz Medical Campus. The Central Committee on Research Involving Human Subjects of the Netherlands (CCMO) gave ethical approval for the work conducted at Erasmus MC, University Medical Center Rotterdam. All participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared Stem Cell Network , FY17/CT1 Canadian Cancer Society Research Institute , CCSRI 703199 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted August 27, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials Sandra Cohen , Elisa Tomellini , Nadia Bambace , Imran Ahmad , Lea Bernard , Jean Roy , Jonathan Gutman , Jurjen Versluis , Pierre Caudrelier , Gabrielle Thauvette , Guy Sauvageau , Filippo Milano medRxiv 2026.08.21.26360802; doi: https://doi.org/10.64898/2026.08.21.26360802 Share This Article: Copy Citation Tools UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials Sandra Cohen , Elisa Tomellini , Nadia Bambace , Imran Ahmad , Lea Bernard , Jean Roy , Jonathan Gutman , Jurjen Versluis , Pierre Caudrelier , Gabrielle Thauvette , Guy Sauvageau , Filippo Milano medRxiv 2026.08.21.26360802; doi: https://doi.org/10.64898/2026.08.21.26360802 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (892) Anesthesia (325) Cardiovascular Medicine (4752) Dentistry and Oral Medicine (473) Dermatology (406) Emergency Medicine (639) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15796) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6963) Geriatric Medicine (725) Health Economics (1050) Health Informatics (4957) Health Policy (1422) Health Systems and Quality Improvement (1730) Hematology (578) HIV/AIDS (1328) Infectious Diseases (except HIV/AIDS) (16226) Intensive Care and Critical Care Medicine (1157) Medical Education (661) Medical Ethics (150) Nephrology (717) Neurology (7156) Nursing (360) Nutrition (1071) Obstetrics and Gynecology (1224) Occupational and Environmental Health (998) Oncology (3561) Ophthalmology (1032) Orthopedics (391) Otolaryngology (444) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1769) Pharmacology and Therapeutics (730) Primary Care Research (758) Psychiatry and Clinical Psychology (5810) Public and Global Health (9662) Radiology and Imaging (2371) Rehabilitation Medicine and Physical Therapy (1426) Respiratory Medicine (1236) Rheumatology (631) Sexual and Reproductive Health (762) Sports Medicine (571) Surgery (761) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Higher dietary antioxidants linked to lower odds of cervical cancer in NHANES analysis](https://medichelpline.com/clinical-feed/medical-news-today-1-study-finds-link-between-antioxidant-rich-diets-and-lower-cervical-cancer-odds.md)
- [Mechanism of response to FHD-286 plus decitabine in advanced myeloid malignancies](https://medichelpline.com/clinical-feed/medrxiv-15-mechanism-of-response-to-fhd-286-and-decitabine-combination-in-patients-with.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.